Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited due to allegations of securities law violations, encouraging affected investors to seek legal recourse [2][4]. Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives made false and misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme and insider trading activities [4]. - Specific allegations include the use of social media misinformation, coordinated dumping of shares by insiders, and omission of artificial trading activity that inflated stock prices [4]. Group 2: Stock Performance - Pomdoctor's stock experienced a significant decline, dropping from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a decline of roughly $0.12 per share or approximately 24% in one trading session [5]. Group 3: Legal Proceedings - Investors who purchased Pomdoctor securities between October 9, 2025, and December 11, 2025, are reminded of the April 13, 2026, deadline to seek the role of lead plaintiff in the federal securities class action against the company [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6].
POM CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Pomdoctor Investors of Securities Class Action Deadline on April 13, 2026